Carlsbad, CA 10/21/08—Invitrogen has announced the acquisition of VisiGen Biotechnologies, a developer of single-molecule sequencing technology, for $21 million in cash. VisiGen’s technology utilizes fluorescence resonance energy transfer technology and massively parallel arrays. Invitrogen Chairman and CEO Gregory Lucier commented that Invitrogen acquired VisiGen for its intellectual property and for the company’s strength in enzymology and other areas that complement Invitrogen’s single-molecule sequencing R&D. He stated, “down the road—three, four years or so—we think single-molecule sequencing could be a very important research and medical tool.”